Netherton Syndrome Clinical Trial
Official title:
A Phase I/II, Multicenter, Randomized, Double-blind, Placebo Within-patient Controlled, First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS)
In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease. SXR1096 is a specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 - all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be treated for one month with active cream and placebo cream at different areas of the skin.
Netherton syndrome is a ultra-rare and very severe form of ichtyosis. It is a mongenetic disease. There is no specific treatment available for Netherton syndrome. In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndrom. SXR1096 is a specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 - all recognised as up-regulated and causing the disease state in Netherton syndrome patients, as these patients have a gene defect in the gene spink5 encoding for the protease inhibitor LEKTI - that will normally regulate the activity of KLK5, 7 and 14 in the stratum corneum of the skin, Patients will be treated for one month with active cream and placebo cream at different areas of the skin. The study will assess the safety and efficacy of the treatment in patients. There will also be pharmacokinetic, pharmacodynamic and biomarker studies conducted. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05979831 -
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT00208026 -
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT05583669 -
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01428297 -
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
|
Phase 1 | |
| Recruiting |
NCT05856526 -
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05789056 -
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05521438 -
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT05388903 -
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04244006 -
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03417856 -
Defining the Skin and Blood Biomarkers of Ichthyosis
|
||
| Completed |
NCT02113904 -
Clinical Trial Using Humira in Netherton Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT06137157 -
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
|
Phase 1 | |
| Completed |
NCT03041038 -
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
|
Phase 2 | |
| Recruiting |
NCT02081313 -
Natural History and Biological Study of Netherton Syndrome
|
N/A | |
| Recruiting |
NCT01545323 -
Gene Therapy for Netherton Syndrome
|
Phase 1 | |
| Not yet recruiting |
NCT05902663 -
Natural History of Netherton Syndrome
|